Mesoblast’s REMESTEMCEL-L “significantly improved outcomes” in patients with inflammatory lung disease and COVID-19
01 Jun 2020 - Mesoblast (ASX:MSB) says its lead mesenchymal stem cell (MSC) product candidate remestemce-L treatment showed significantly improved outcomes for patients with chronic obstructive pulmonary disease (COPD).